Drug intelligence / Profile preview

NTX1060

Development stage: Preclinical
Lead developer: Nectin Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NTX1060 is an antibody-drug conjugate (ADC) being developed by Nectin Therapeutics for the treatment of solid and hematological malignancies. It specifically targets the Poliovirus Receptor (PVR; CD155), a cell surface glycoprotein that is highly expressed on the surface of many cancer cells and plays a key role in tumor cell invasion and immune suppression by interacting with receptors such as TIGIT and CD96. NTX1060 is designed to bind to PVR-expressing cells and deliver a potent cytotoxic payload, leading to selective tumor cell destruction. The drug is currently in the IND-enabling phase of development.

Targets

PVR

Beyond the preview

Go deeper on NTX1060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX1060.

Explore the full profile